PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
- 19 February 2021
- journal article
- review article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 205-212
- https://doi.org/10.1016/j.jcf.2021.02.003
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
This publication has 61 references indexed in Scilit:
- Cirrhosis and other liver disease in cystic fibrosisJournal of Cystic Fibrosis, 2013
- Better Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with Cystic FibrosisThe Journal of Pediatrics, 2013
- Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot studyPediatric Diabetes, 2013
- Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitusJournal of Cystic Fibrosis, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Non-Invasive markers for hepatic fibrosisBMC Gastroenterology, 2011
- Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related DiabetesDiabetes Care, 2010
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationThe New England Journal of Medicine, 2010
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009